Technical Analysis for OPK - OPKO Health Inc.

Grade Last Price % Change Price Change
grade F 2.53 -6.99% -0.19
OPK closed down 6.99 percent on Friday, March 22, 2019, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Flat
See historical OPK trend table...

Date Alert Name Type % Chg
Mar 22 Fell Below 20 DMA Bearish 0.00%
Mar 22 180 Bearish Setup Bearish Swing Setup 0.00%
Mar 21 Crossed Above 20 DMA Bullish -6.99%
Mar 21 Pocket Pivot Bullish Swing Setup -6.99%
Mar 21 Gapped Up Strength -6.99%
Mar 18 Oversold Stochastic Weakness 0.40%
Mar 15 Pocket Pivot Bullish Swing Setup 0.80%
Mar 15 Inside Day Range Contraction 0.80%
Mar 15 Oversold Stochastic Weakness 0.80%
Mar 14 New 52 Week Closing Low Bearish 4.55%

Older signals for OPK ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Opko Health, Inc., a pharmaceutical and diagnostics company, engages in the discovery, development, and commercialization of novel and proprietary technologies. It operates in two segments, Pharmaceuticals and Diagnostics. The company is developing molecular diagnostics tests to identify molecules or immunobiomarkers for Alzheimer's disease, non-small cell lung cancer, and pancreatic cancer, and other cancers; point-of-care diagnostic tests to detect prostate specific antigen; and laboratory developed tests comprising 4Kscore test for the detection of prostate cancer. It also operates OURLab, a full-service medical laboratory specializing in urologic pathology. In addition, the company is developing CTAP101 Capsules to treat secondary hyperparathyroidism in patients with stage 3 or 4 chronic kidney disease and vitamin D insufficiency; and Fermagate Tablets to treat hyperphosphatemia in end-stage renal disease patients on chronic hemodialysis. Further, it is developing oligonucleotide therapeutics, which are under pre-clinical studies for the treatment of various illnesses, such as cancer, heart disease, metabolic disorders, and genetic anomalies; heparin-derived oligosaccharide for asthma and chronic obstructive pulmonary diseases; influenza vaccines; alpha-galactosyl ceramide analogs for cancer, infectious disease, and autoimmune disease; and rolapitant, a NK-1 candidate that has completed Phase II clinical testing for the prevention of chemotherapy induced nausea and vomiting. Additionally, the company develops and produces specialty active pharmaceutical ingredients; offers ophthalmic and other pharmaceutical products; and provides cardiovascular products, vaccines, antibiotics, gastro-intestinal products, and hormones. It operates in the United States, Chile, Mexico, Israel, and Spain. OPKO Health, Inc. is based in Miami, Florida.
Health Cancer Alpha Chemotherapy Cancers Clinical Trial Pharmaceutical Industry In China Prostate Cancer Non Small Cell Lung Cancer Alzheimer's Disease Influenza Asthma Medical Tests Active Pharmaceutical Ingredients Antibiotics Diagnostic Tests Chronic Kidney Disease Pancreatic Cancer End Stage Renal Disease Hemodialysis Molecular Diagnostics Infectious Disease Nausea Autoimmune Disease Vomiting Metabolic Disorders Cardiovascular Products Heart Disease Chronic Obstructive Pulmonary Diseases Organ Failure Secondary Hyperparathyroidism Hyperphosphatemia Such As Cancer
Is OPK a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 6.4
52 Week Low 2.34
Average Volume 5,526,045
200-Day Moving Average 3.9776
50-Day Moving Average 3.02
20-Day Moving Average 2.598
10-Day Moving Average 2.533
Average True Range 0.1508
ADX 33.05
+DI 17.968
-DI 26.1651
Chandelier Exit (Long, 3 ATRs ) 2.4276
Chandelier Exit (Short, 3 ATRs ) 2.8524
Upper Bollinger Band 2.841
Lower Bollinger Band 2.355
Percent B (%b) 0.36
BandWidth 18.706697
MACD Line -0.1124
MACD Signal Line -0.1411
MACD Histogram 0.0287
Fundamentals Value
Market Cap 1.42 Billion
Num Shares 559 Million
EPS -0.15
Price-to-Earnings (P/E) Ratio -16.87
Price-to-Sales 3.13
Price-to-Book 1.76
PEG Ratio -2.91
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.83
Resistance 3 (R3) 2.86 2.79 2.78
Resistance 2 (R2) 2.79 2.71 2.78 2.76
Resistance 1 (R1) 2.66 2.67 2.63 2.63 2.75
Pivot Point 2.59 2.59 2.57 2.58 2.59
Support 1 (S1) 2.46 2.51 2.43 2.43 2.31
Support 2 (S2) 2.39 2.47 2.38 2.30
Support 3 (S3) 2.26 2.39 2.28
Support 4 (S4) 2.23